This article explains everything you need to know about GLP-1 agonists and whether these medications can help with weight loss and type 2 diabetes
NICE NG28 recommends prioritising SGLT-2 inhibitors in people with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease often alongside or instead of metformin due to these organ-protective effects [10] [8] GLP-1 receptor agonists (e.g., semaglutide, liraglutide) generally produce greater HbA1c reductions (1.01.5%) and significant weight loss, but are injectable and more costly
Protective effect of propionyl-L-carnitine against PAF-induced rat paw oedema
The licensed options still need to be matched to your weight trend, appetite, tolerability and health goals
Of note, SGLT2 inhibitors also reduce cardiovascular mortality or hospitalization for heart failure, thus showing benefits across the cardiorenal axis
1, 2024 from US Food & Drug Administration (FDA-a)